| Name | LAT1-IN-1 |
| Description | LAT1-IN-1 (BCH) is a selective and competitive inhibitor of L-type amino acid transporter protein 1 (LAT1). LAT1-IN-1 has antitumor activity, inducing apoptosis in tumor cells and inhibiting cell proliferation. |
| In vitro | LAT1-IN-1 (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased.LAT1-IN-1 (1-100 mM;?3 days;?KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner.?LAT1-IN-1 (30 mM;?24 and 48 hours;?KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that LAT1-IN-1 induces cell cycle arrest at G1 phase. |
| In vivo | LAT1-IN-1 (200 mg/kg;?intravenous injection;?daily;?for 14 days;?male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo. |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 12.5 mg/mL (80.55 mM), Sonication is recommended.
DMSO : < 1 mg/mL, insoluble or slightly soluble
|
| Keywords | LAT-1-IN-1 | inhibit | LAT1 IN 1 | LAT1-IN-1 | LAT1IN1 | Apoptosis | Inhibitor |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
